{"name":"Melanoma and Skin Cancer Trials Limited","slug":"melanoma-and-skin-cancer-trials-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sirolimus Topical Cream","genericName":"Sirolimus Topical Cream","slug":"sirolimus-topical-cream","indication":"Melanoma (topical treatment)","status":"phase_3"}]}],"pipeline":[{"name":"Sirolimus Topical Cream","genericName":"Sirolimus Topical Cream","slug":"sirolimus-topical-cream","phase":"phase_3","mechanism":"Sirolimus is an mTOR inhibitor that suppresses immune cell proliferation and angiogenesis when applied topically to skin lesions.","indications":["Melanoma (topical treatment)","Non-melanoma skin cancer (topical treatment)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOSldIWGd2V0U5emhUemxzc2JydHpVUG8zWjdfS1dPbXBPTXVQZFhmaXdET2M0UnUyZVpLR3FDUFZ2QkpQUWdlV0d1cDIzRGdnbnI0cnZ5eHhSUmVWdEgtaFlXNFh0dklCSUprUVNmUFo3ZTRHUFVvdEpSZDRsakd6bHlwREtxVkNkcXlQUkJQZUlvU1lEUWdwckxOY0hJZWxpLVlLbHQzbkFqM2JEalJV?oc=5","date":"2026-04-01","type":"trial","source":"Stock Titan","summary":"Skin cancer study points to stronger results at higher SkinJect dose - Stock Titan","headline":"Skin cancer study points to stronger results at higher SkinJect dose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNbkV3dGVuOUEzLVJXV3h6Y001TDcwdWdoLTdQTFZVS0tWVmp0WWVHTUJ4cFdFdzZlNW0zNWZ1VXJYMVVvcWRGbFpBTklxTHVRSGNxUElmY3ZKbHpNTFV4V2djQTlpWjlmQ3pyVmVoR3RsSW5La1I1MVNocFRmYS0tNndXMldsX2g5SXR1bEQxc2c1dTlNRzhqa1NLRklZTXlvN256Yk9OOTBDQ0I2OXhKMTZjZDlJaG85ajNNbU9rMlp1Y2xBX0pCVlhUMUVaeldndFJmeklTRWJqdw?oc=5","date":"2026-03-30","type":"trial","source":"Sahm","summary":"Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate - Sahm","headline":"Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxOSUUzMnltaXJaTlM5YTQ0cWpJcHAxVzlneDZ4MHp3QlpBcVB5N1FvUVUwUGw3R0xwVTF6Si0xOER5U2RfWEJxdS1EeERvcVNTNDZUdVdVQ24xbjFNM0JHQjR3OE82QWdkMFhpZ1JzTzZLZlpRWnNJQmdJcno2cmQ0TzBFT0N0RUtUWnpURnhrX191al9NOXRLZWpPdjJtVEEwZGd3bU81UHdBVnB2TVdJRGQzU2REdmhJQTlhSlV2azB4QkkyZlFoMjZxYnVzekZoRnNrcjhJUWMxZTNmQTFIdUJma1JMVlk4UW9nN0gwaUE2ekNvRlBWbVRweG9lSHNDazU5dtIBigJBVV95cUxNVDVxZWYzOXhUY2s1bWRtLUxTYWdaZFd6d0cwQmtxT3ItQjJQVVhXZ1BVTnlac1lHZF9MeS0xTzJXTk1FUVdwYXQzR0w1YzVNdl9acFZBZ3h2RURibS1IdUlKQXAydVRSQk1IQ0p4MEFOSEtNLVRPUkF0NHI1bnZvazV2S2Q3dlQ5UzYzYWtBeldVYnV5a3I4X3VoU1ltNUNLaURaV1I0TUFJRHdmdVB1czRiRVFaUmtVLVctZDJRQ1V1UjVNV3lVYlRDUk43MzFhTVdSVVcwLVhFSndrOUJLX1E0dTJVMGpuanNsRTgzeVZ4eFhTSVlSZ3lOUnRxLUlUa0J2blhnSmdvZw?oc=5","date":"2026-03-30","type":"trial","source":"ET Pharma","summary":"Sun Pharma’s Cancer candidate Fibromun fails to meet primary endpoints in mid-stage studies - ET Pharma","headline":"Sun Pharma’s Cancer candidate Fibromun fails to meet primary endpoints in mid-stage studies","sentiment":"negative"},{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"trial","source":"Medical Dialogues","summary":"Setback to Sun Pharma as Fibromun, Nidlegy Trials Miss Key Endpoints in Cancer Studies - Medical Dialogues","headline":"Setback to Sun Pharma as Fibromun, Nidlegy Trials Miss Key Endpoints in Cancer Studies","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNdV9aT0JKdEZiaFd1WC1uc1lNOC1hOHY4OXFaaVdUMkhoLVdYejFpTXVJNmF5TWtMSUF3Qng4SGIxUjJTMHp1RGszVnBiOURRVnFPS3o0Ykx1b0p6Wi1LSy1DZ1dpTmdSWEt3Q1FnamRzX0oxNjQ3M0xEZzlaRXlvdnRhMl9zZG95M21BWFVkck5hTHVEbE5NUXdSOTdzbG0wT1Q0eDgtTU9wMXhWWkJRbElHN2IyV3FySEV6dEhsd0pVN21wb1NJX0JJWVh0ZUkxQW9r?oc=5","date":"2026-03-28","type":"trial","source":"scanx.trade","summary":"Sun Pharma Partner Philogen Reports Mixed Phase II Results, Plans Registrational Studies - scanx.trade","headline":"Sun Pharma Partner Philogen Reports Mixed Phase II Results, Plans Registrational Studies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQ3pYb2JUZ3N4eGo5ay1zdVpVa2t0aEZlM1F1TTJycUxGaGtvZW1KRF8wZlZUejdNN1hoTTRBdGFBMmdkZzUyeWs2akFVMXdqWE9RLWVTUW9lVnlEV0xzaW9iWnJoa2s0T09NRS1NZ3dRdHZvOVlBbkF4dnpoU1UxYUtnMHgxOHNXN1djUDRuS3lmV1BtWVJTZnBlY2tjeWV5a21GY3FqTlBWNXM4QzZEck91NzdoamU1OFpVbmpuXy0?oc=5","date":"2026-03-26","type":"trial","source":"Stock Titan","summary":"Three in four lesions cleared in Medicus skin cancer study at Day 57 - Stock Titan","headline":"Three in four lesions cleared in Medicus skin cancer study at Day 57","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQN2VCNFpkVEpxVGlPUm0za0dydzRWcjhSUmZkWnRqeXdZUnpHc05LMzNPdDV1dnBfMDRsVnQ2d0RXemtKVFpVV2FQQTdLSnNaVVVsRzNKVlZpaDl1bkxEbU9nbVA5N1Z4cW9EbEYtcDdTbW9SRXUzZ1J0eEVlMHRET3Niemxocy1UZXBaWloxMlQ4UTFack5MR1Jwdnd0Uk4yVEhrVXRBbHF3QW1pdVVISDlGdDlCMmx4Uk5EcHowTUZpWld4cm1kS1A2Z212NWMwY05NT29xckxGVTZfbEQzWU5QZy0zQXRTb0loUU1fZ3lvaWs?oc=5","date":"2026-02-10","type":"trial","source":"newsfilecorp.com","summary":"Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial - newsfilecorp.com","headline":"Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Tri","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPMUdPTnphSlZhdUhtd2FLdUJ2OVNqOWw0S2NERm15XzBUM3Zma2ZJMUY0a0gxTWtXcDR5SF9KRjBhSGx0YkNNWkFWVzhoOW1YenkzTUgtY2wybDI3aHl2NFczblJlZUFncjJFSnVienpjS0NidjRMaTItZFhiaGVQckdoZw?oc=5","date":"2026-01-21","type":"trial","source":"pharmaphorum","summary":"Data builds behind Moderna's skin cancer vaccine - pharmaphorum","headline":"Data builds behind Moderna's skin cancer vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTjhXbm1hSTRwWDRDd3RnS08tNjI0RndncXlvS2JYZHFrRzBJcnpJMG54NVlDX28zal9pMGFvLU1lb1djODM3cnVpcHg4dHNGUk9hdEstLXJYb0kyWUE1ZEFfLVc0NkNObTdpRlI5WUlTaTFySTVHbjdoWXJlb2pxaHl4YmZUNkpQUEVCYURDbnVlNjNnX2d3bXlsVnlMOUpYamNhVS1helpTNmpEZ1B4ZUtjbXRqX1F1N2RuMWVmQkpQdw?oc=5","date":"2025-12-15","type":"trial","source":"Dermatology Times","summary":"Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC - Dermatology Times","headline":"Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQZ1pFc0JIN2cxd2lnTmFsM0VueWg0ZHdFZE54VjZOQUZRWHZVM2w4OW5EWmhFeG0xRDV4a1NkQU12SFQzMlZLejB1RndRQjJkbVQyRW4tRVpqaUdSdnMyZUl6OGVxLTB4Y0ZtaG9BYVByRUtTTTBKQVBHWVVwdzcwSUVjYmNxVExrUGsxQm9VQlRlbkNTenozNlRwQWRsYXFKQmQ0WVZLVzgwV0lwcXJ1VzZFNTZkbnlzNXZLRnB2NkRlUmlqN1dFWndXajBVcnc1dG53SDlhSEpxSXVvTHItMnpBcjhXNmFmQWpHano0amp6cDMyNnc?oc=5","date":"2025-11-03","type":"trial","source":"newsfilecorp.com","summary":"Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial - newsfilecorp.com","headline":"Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Tria","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWXA4TFpjWmk0N3lUdmsxdTVWV3oyeFkwX1pfRW9kWVF1SnlaVG53bDg2Q1BpUVZxNUt2bGNQNU5OTUdiYmNmU0t0ZWczU0VldVZOeTJzbDdXN2FnYmVsaklBOEp1UVFBX2YzOENpNHZObXBiME9pTlRkYmJ4bFBVbHR1MDA3UWQ1LTlvTURzU2FpdnliSGtkR0t1cFh1V09qWXdDUGQ2MWw3NWc?oc=5","date":"2025-09-08","type":"trial","source":"Dermatology Times","summary":"Medicus Moves Forward in UAE Trial for Novel, Non-Invasive BCC Therapy - Dermatology Times","headline":"Medicus Moves Forward in UAE Trial for Novel, Non-Invasive BCC Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMDhobHpZX3FBdGI5NnljTWt5R2VWUjZ4R0E2Uy1nTGhfS3EtcGVldjZPVVdQYUlyd19fM1M5bldfZU1Rb2xBM0tsYkx3Um5tZE1aVWstT0thTEJadEhSRUdBZlJTZF9HcU9vRngycFdYUExyMnRxbHBQR3hLQzdVUGkzbGVpUXVHWWJ5R1cyQjhfd09lRlQySFRkanRkZEk3RFdYdXBFZXJrZw?oc=5","date":"2025-08-21","type":"regulatory","source":"Fierce Biotech","summary":"Krystal discontinues melanoma trial after FDA's Replimune rebuff - Fierce Biotech","headline":"Krystal discontinues melanoma trial after FDA's Replimune rebuff","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}